Vaibhav Sahai, MD
Medical Oncology · Ann Arbor, MINPI 1992904023
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,383 of the $79,551 with a category attached, or 73.4%. It is spread thinly across 14 manufacturers, the largest accounting for just 19.6%. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $1304.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$16K
- Incyte Corporation$14K
- AstraZeneca$13K
- Servier Affaires Medicales$12K
- Exelixis Inc.$5K
- Agios Pharmaceuticals, Inc.$4K
- plus $17K from 8 others
Across 171 payments — averaging $30,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$4.4M
- Servier Bioinnovation$186K
- Clovis Oncology, Inc.$140K
- Incyte Corporation$113K
- Servier Pharmaceuticals LLC$97K
- Exelixis Inc.$82K
- plus $310K from 11 others
What the payments were for
- Consulting fees$58,38373%
- Speaking & faculty fees$13,13417%
- Travel & lodging$6,8909%
- Food & beverage$1,1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 14 | $15,566 |
| Incyte Corporation | 14 | $13,655 |
| AstraZeneca | 7 | $12,870 |
| Servier Affaires Medicales | 2 | $11,701 |
| Exelixis Inc. | 8 | $4,824 |
| Agios Pharmaceuticals, Inc. | 5 | $3,667 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $3,150 |
| GSK | 1 | $2,600 |
| Delcath Systems | 1 | $2,500 |
| Astrazeneca UK Limited | 1 | $2,398 |
| Jazz Pharmaceuticals Inc. | 1 | $2,340 |
| Servier Pharmaceuticals LLC | 1 | $1,950 |
| Taiho Oncology, Inc. | 2 | $1,742 |
| Astrazeneca AB | 3 | $590 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,551 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 44 | $101,633 |
| ZenpepLipase/Protease/Amylase | 20 | $86,520 |
| EliquisApixaban | 41 | $25,662 |
| Prochlorperazine Maleate | 28 | $608 |
| Ondansetron Hcl | 29 | $341 |
| Olanzapine | 15 | $305 |
| Omeprazole | 24 | $288 |
| Gabapentin | 16 | $193 |
| Levothyroxine Sodium | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ann Arbor
- Harry ErbaAnn Arbor$1.1M
- Frank WeinbergAnn Arbor$195K
- Francis WordenAnn Arbor$142K
- Maha HussainAnn Arbor$114K
- Moshe TalpazAnn Arbor$83K
- Howard TerebeloAnn Arbor$47K
- Angel QinAnn Arbor$41K
- Erin CobainAnn Arbor$38K
- Phillip PalmbosAnn Arbor$37K
- Rashmi ChughAnn Arbor$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.